. 2015 Jul 14;68(2):241–253. doi: 10.1111/his.12745

Table 1.

Clinicopathological patient characteristics of the gastric cancer cohort

	Valid (n)	Missing (n)		Total (n)	MET negative [n (%)]	MET positive [n (%)]	P‐value
Gender	470	0	Men	291	265 (91.1)	26 (8.9)	0.041^a
Gender	470	0	Women	179	172 (96.1)	7 (3.9)	0.041^a
Age	470	0	<68 years	233	214 (91.8)	19 (8.2)	0.371^a
Age	470	0	≥68 years	237	223 (94.1)	14 (5.9)	0.371^a
Localization	470	0	Proximal stomach	143	128 (89.5)	15 (10.5)	0.075^a
Localization	470	0	Distal stomach	327	309 (94.5)	18 (5.5)	0.075^a
Laurén phenotype	470	0	Intestinal	241	228 (94.6)	13 (5.4)	0.060^a
			Diffuse	147	137 (93.2)	10 (6.8)
			Mixed	31	25 (80.6)	6 (19.4)
			Unclassified	51	47 (92.2)	4 (7.8)
Mucin phenotype	412	58	Intestinal	117	113 (96.6)	4 (3.4)	0.237^a
			Gastric	62	57 (91.9)	5 (8.1)
			Mixed	169	153 (90.5)	16 (9.5)
			Unclassified	64	60 (93.8)	4 (6.2)
pT‐category	470	0	pT1a/b	59	57 (96.6)	2 (3.4)	0.043^b
			pT2	56	55 (98.2)	1 (1.8)
			pT3	184	170 (92.4)	14 (7.6)
			pT4a/b	171	155 (90.6)	16 (9.4)
pN‐category	469	1	pN0	134	131 (97.8)	3 (2.2)	0.004^b
			pN1	65	64 (98.5)	1 (1.5)
			pN2	85	74 (87.1)	11 (12.9)
			pN3 (a/b)	185	167 (90.3)	18 (9.7)
Lymph node ratio	468	2	<0.189	229	221 (96.5)	8 (3.5)	0.004^a
Lymph node ratio	468	2	≥0.189	239	214 (89.5)	25 (10.5)	0.004^a
Stage (UICC)	470	0	IA	46	45 (97.8)	1 (2.2)	<0.001^b
			IB	36	36 (100.0)	0 (0.0)
			IIA	55	54 (98.2)	1 (1.8)
			IIB	46	43 (93.5)	3 (6.5)
			IIIA	55	51 (92.7)	4 (7.3)
			IIIB	80	73 (91.2)	7 (8.8)
			IIIC	64	58 (90.6)	6 (9.4)
			IV	88	77 (87.5)	11 (12.5)
Lymphatic invasion	455	15	pL0	221	214 (96.8)	7 (3.2)	0.003^a
Lymphatic invasion	455	15	pL1	234	210 (89.7)	24 (10.3)	0.003^a
Venous invasion	454	16	pV0	403	379 (94.0)	24 (6.0)	0.068^a
Venous invasion	454	16	pV1	51	44 (86.3)	7 (13.7)	0.068^a
Tumour grade	469	1	G1/G2	112	110 (98.2)	2 (1.8)	0.010^a
Tumour grade	469	1	G3/G4	357	326 (91.3)	31 (8.7)	0.010^a
R‐status	470	0	pR0	410	387 (94.4)	23 (5.6)	0.005^a
R‐status	470	0	pR1	60	50 (83.3)	10 (16.7)	0.005^a
Survival	455	15	Total	455	425 (93.4)	30 (6.6)
Survival	455	15	Dead	354	325 (91.8)	29 (8.2)
			Median (months ± SD; 95%CI)		16.69 ± 1.42 (13.90–19.48)	5.42 ± 0.97 (3.53–7.32)	<0.001^c
Helicobacter pylori	402	68	Positive	60	56 (93.3)	4 (6.7)	0.769^a
Helicobacter pylori	402	68	Negative	342	322 (94.2)	20 (5.8)	0.769^a
EBV	453	17	Positive	17	15 (88.2)	2 (11.8)	0.356^a
EBV	453	17	Negative	436	405 (92.9)	31 (7.1)	0.356^a
KRAS	470	0	Wild‐type	453	420 (92.7)	33 (7.3)	0.622^a
KRAS	470	0	Mutant	17	17 (100.0)	0	0.622^a
PIK3CA	470	0	Wild‐type	450	417 (92.7)	33 (7.3)	0.384^a
PIK3CA	470	0	Mutant	20	20 (100.0)	0 (0.0)	0.384^a
MSI status	441	29	MSS	407	376 (92.4)	31 (7.6)	0.155^a
MSI status	441	29	MSI high	34	34 (100.0)	0	0.155^a
HER2	443	27	Positive	36	35 (97.2)	1 (2.8)	0.497^a
HER2	443	27	Negative	407	377 (92.6)	30 (7.4)	0.497^a

EBV, Epstein–Barr virus; MSI, Microsatellite instability; HER2, Human epidermal growth factor receptor 2; SD, Standard deviation; MET, Hepatocyte growth factor receptor; UICC, Union for International Cancer Control.

Fisher's exact test.

Kendall's tau test.

Log‐rank test.